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ABSTRACT
Inflammation is a definite cancer-causing factor as re-
vealed by cumulative basic, clinical and epidemiologi-
cal studies. It is mostly induced by infectious agents. 
For instance, infection with papillomaviruses associates 
with anogenital cancers, especially cervical cancers; 
Helicobacter pylori infection of the stomach tends to 
increase the risk of stomach cancer; chronic hepatitis 
B & C viruses and fluke infections of the liver increase 
liver cancers; autoimmune diseases, e.g., inflammatory 
bowel diseases, associate with development of colorec-
tal cancer, and aerial irritants (foreign bodies) such as 
asbestos or fine particulate matter (PM2.5) in outdoor 
air increase malignant pleural mesotheliomas or lung 
cancers. These are typical examples of inflammation-
related carcinogenesis. It is apparent that the pathogens 
to induce inflammatory reactions in specific organs 
are not related to each other. However, the underlying 
pathogenesis in common is to induce and/or sustain 
inflammation. In this article, I would like to review the 
up-to-date findings of epidemiological trends, causes 
and mechanisms of inflammation-related carcinogen-
esis. 
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Cancer is classified as noncommunicable disease as 
cardiovascular diseases, chronic respiratory diseases 
and diabetes are. They are mostly chronic diseases of 
long duration and generally slow development. While 
they are assumed to develop from aging, urbanization, 
and unhealthy lifestyles, it has also become known that 
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low-grade chronic inflammation, which is characterized 
by increased systemic levels of inflammatory cytokines 
and inflammation-responsible protein (C-reactive 
protein), is one of the underlying key mechanisms.1 
Indeed, estimated 20–25% of all cases of cancer 
worldwide are associated with inflammation induced by 
microbial infection. Extended life span, dietary factors 
and physical inactivity; mutation and replicating errors; 
environmental pollutants including aerial irritants and 
tobacco; and radiation and ultraviolet are linked to car-
cinogenesis today. Nevertheless, persistent inflamma-
tion resulting from infection or autoimmunity is most 
evidently associated with the onset of carcinogenesis.2
 The relation of inflammation to cancer was first 
postulated by Galenus around 1,800 years ago.3 He pro-
posed that tumors arose from inflammatory tissue injury 
and that the tumors and the tissue were pathophysi-
ologically similar.3 Centuries later in 1863, Virchow 
confirmed Galenus’s hypothesis from his own observa-
tion that lymphoreticular infiltrates, namely inflamma-
tion, preceded tumor development.4 This possible link 
between injurious inflammation and cancer was also 
pointed out later by Dvorak who revealed that tumor tis-
sues resembled wound tissues because both tissues were 
composed of similar stromal cell types such as infiltrat-
ed inflammatory cells and angiogenesis-related cells; the 
only difference he pointed out was that tumor tissues did 
not terminate (heal) but wound healed finally.5 
 Undoubtedly antitumor immunity exists, since par-
ticular kinds of tumors are formed only in patients with 
iatrogenic immunosuppression such as melanoma and 
nonmelanoma skin cancer in organ transplant recipi-
ents, lymphoma in patients with lymphoproliferative 
disorders, or Kaposi’s sarcoma in patients with immu-
nosuppressive infection such as with HIV. However, 
the generality of the arising tumors are sarcomas and 
hematologic malignancies, and carcinomas that account 
for the majority of human carcinogenesis seldom occur 
in the immunosuppressed patients. Discussions have 
suggested that antitumor immunity might work only in 
the very initial phase of carcinogenesis or work against 
particular kinds of tumorigenesis only. An opinion has 
even suggested that antitumor immune effector cells 
may act as stimulant to carcinogenesis. In the 1970s, 
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Prehn proposed that immune effector cells contributed 
to carcinogenesis, and named the phenomenon as “im-
munostimulation theory of tumor development.”6
 From the achievements of our predecessors carried 
out over the two millennia, we have solid evidence that 
an inflammatory environment can be an essential risk 
for induction of various types of carcinomas. Recent 
results add that inflammation-related carcinogenesis is 
influenced not only by individual age and sex, but also 
by regional/geographical and economical development 
statuses of country. I review the current evidence on the 
inflammation-related carcinogenesis and propose pos-
sibly effective preventive/therapeutic strategies based on 
our elucidation of inflammation mechanism obtained by 
using our animal model. 
EPIDEMIOLOGICAL TREND OF INFLAMMATION-
RELATED CARCINOGENESIS
It is obvious that incidences of inflammation-related 
cancers are not in a homogenous background but in a 
complex one influenced by individual age, sex, living 
region, era and also development status of country as 
revealed in the recent epidemiological studies.
 Chronologically the incidences of inflammation-
related carcinogenesis also differ. In the United States, 
cancer epidemiologists estimated in the 1980’s that 
around 75% of cancers was due to three cancer-causing 
factors: daily diet, smoking and infection/inflammation.7 
Currently the three major factors are thought to account 
for 43% of cancer causes.8 Involvement of inflammation 
in the total cancer incidences was reduced from 10% to 
5%.9
 There are geographical differences in the incidences 
of inflammation-caused cancers. Namely, contribution 
of inflammation to carcinogenesis greatly varies among 
continentals, countries, and even in the regions within a 
country. Figure 1 shows the ratios of infection/inflam-
mation to all the cancer death causes: around 25% in 
sub-Saharan Africa, around 6% in Europe.8 In general, 
the proportions were higher in less developed countries 
(23%) than in more developed countries (7%) including 
North America and Europe (10). Lowest ratios were in 
Australia and New Zealand (3%), while other parts of 
Oceania showed higher ratios (18%). In contrast to the 
highest ratio in sub-Saharan Africa (25%), the rates are 
lower in North Africa and west Asia (13%). In east Asia, 
the rates are high: Japan (20%), China (26%), South Ko-
rea (21%) and India (21%).10 Considering the high ratios, 
east Asia including Japan is still a developing region.
 The geographical and regional differences in the 
incidences of inflammation-related carcinogenesis may 
arise from the economic standing or development status 
of each country; i.e., the standard of life, the levels of 
medical care and education, etc. will make up the char-
acteristic of a country as a whole. In addition, prevalence 
of the four main infectious agents, HPV, HBV, HCV and 
Helicobacter pylori, differs among economically and 
geographically different regions. Relative contribution of 
HPV to cancer burden is similar in both developed and 
developing countries. However, that of Helicobacter py-
lori is larger in developed countries, and those of HBV 
and HCV are larger in developing countries.10 
 There were estimated 14.1 million new cancer cases 
and 8.2 million cancer deaths globally in 2012; of the 
cancer deaths, about 65% (5.3 million) was in less de-
veloped countries.11 Since the infectious agents account 
for as much as 20% of all of the cancer-causing factors, 
we could estimate that around 2.8 million new cancer 
cases and around 1.7 million deaths would be attribut-
able to infection/inflammation. It is greatly apprehended 
that new cancer cases/deaths due to inflammation would 
increase rapidly in the developing countries within a few 
decades as a result of upcoming population growth.12 
 Although the total number of cancer cases due to 
inflammation is much the same between men and wom-
en,10 there are some sex- and age-dependent differences 
in particular cancers: stomach cancer, liver cancer, oro-
pharynx cancer, bladder cancer, Hodgkin’s lymphoma 
and Kaposi’s sarcoma are much higher in men than in 
women.10 And it is obvious that around 30% of inflam-
mation-related cancers (cervical cancer, Hodgkin’s lym-
phoma and Kaposi’s sarcoma) are in individuals younger 
than 50 years, compared to other inflammation-related 
cancers which develop mostly in those older that 50 
years.10 
 
CAUSES OF INFLAMMATION-RELATED CAR-
CINOGENESIS
Infections induced by certain viruses, bacteria, parasites 
or foreign bodies and following prolonged inflammation 
have been identified as grave risk factors for develop-
ment of specific cancers. Table 1 shows infectious agents 
classified as definitely carcinogenic to humans by the 
International Agency for Research on Cancer and those 
classified as presumably carcinogenic according to ex-
perimental and clinical reports.10
 
MECHANISMS OF INFLAMMATION-RELATED 
CARCINOGENESIS DETERMINED IN AN EX-
PERIMENTAL MODEL
Close association between inflammation and carcino-
genesis has been indicated by clinical and epidemio-
logical studies; however, there is hardly a solid animal 
model in which carcinogenesis by inflammation can 
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Fig. 1. Causes of cancer differ from country to country. Europe, excluding east Europe; Africa, representing sub-Saharan countries only.  
be evidently observed. To demonstrate the direct link 
between inflammation and carcinogenesis, our group 
established several animal models in which tumorigenic 
conversion or acceleration of carcinogenic processes 
of rat, mouse or human cells occurs in the presence of 
inflammation. In this section, I summarize the results 
of our thorough investigation using one of our mouse 
models and introduce our elucidation of the mechanism 
responsible for inflammation-related carcinogenesis and 
theoretical preventive strategies.   
 To establish the experimental model for carcino 
genesis especially focusing on acquisition of tumori 
genicity in vivo, we had to choose cells which were 
immortalized, non-tumorigenic, and non-metastatic 
but would grow in vitro, bearing the concept of 
xenogenization in mind. “Xenogenization of tumor 
cells” is the term meaning immunologically spontaneous 
regression of tumor cells which have been infected 
with xenogeneic viruses,13 transfected with the genes 
coding allogeneic antigen,14 or exposed to mutagenic 
chemicals,15 after injected into normal syngeneic host.  
 We obtained regressive clonal QR cells from clonal 
tumorigenic fibrosarcoma cells, BMT-11 cl-9, by expos-
ing them in vitro to a mutagen/carcinogen (quercetin); 
they were non-tumorigenic and non-metastatic in nor-
mal syngeneic C57BL/6 mice, and we termed the phe-
nomenon as “chemical xenogenization of tumor cells.”15 
By using the regressive QR cells, we can easily detect 
internal/external factors which are closely associated 
with carcinogenic process through the conversion of 
their regressive phenotypes into lethally tumorigenic 
ones, after injecting QR cells previously treated in vitro 
with a candidate material, or co-implanting QR cells 
with it, into mice. As shown in the Fig. 2A, QR cells did 
not develop tumor after (2 × 105 cells) subcutaneously 
injected into mice.15 Since QR cells grew progressively 
in immunosuppressed hosts, we determined that their 
regression was mediated by host immunity.16 
 
Infiltrated inflammatory cells are necessary and 
sufficient to accelerate carcinogenesis 
A serendipitous finding was that the regressive QR cells 
were spontaneously converted to grow lethal after im-
planted into a pre-inserted piece of hemostasis gelatin 
sponge which induced foreign-body-reactive inflam-
mation at the implantation site (Fig. 2B).17 Significance 
of the foreign-body-induced inflammation on carcino-
genesis was confirmed by using other materials such as 
plastic plate. In this case, too, various phenotypic altera-
tions occurred following QR cell conversion.18 All of the 
arising tumors were found to have acquired tumorigenic 
and metastatic phenotypes, and the acquired malignant 
phenotypes remained stable as far as examined for de-
cades at least under cultivation in vitro. An increase in 
prostaglandin E2 production followed the acquisition 
of tumor-forming ability, which particularly suppressed 
immunological host-defense against tumors. Angio-
genesis, motility and invasion capacities of tumorigenic 
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Table 1. Definitely and presumably carcinogenic agents in inflammation-related carcinogenesis in human
Sites of inflammation- Causes of inflammation/pathological condition
related carcinogenesis Definitely carcinogenic Presumably carcinogenic
Eye  HIV type 1 UV-associated skin inflammation
Lip  UV-associated skin inflammation
Oral cavity HPV type 16 HPV type 18, gingivitis, lichen planus, leukoplakia
Salivary gland  Sialadentis
Tongue  HPV, caries, gingivitis
Tonsils HPV type 16
Nasopharynx EBV 
Pharynx  HPV type 16 Asbestos
Oropharynx  HPV 
Larynx Asbestos  HPV type 16 
Thyroid  Chronic lymphocytic thyroiditis, Hashimoto’s thyroiditis 
Esophagus  Gastric reflux, esophagitis, Burrett’s esophagus, 
  Neisseria mucosa, Neisseria sicca, Neisseria subflava
Lung Asbestos, coal gasification, outdoor  Asthma, bronchitis, COPD, interstitial pneumonia, sarcoidosis, 
 air pollution,* tobacco smoke silicosis, tuberculosis, Chlamydia pneumoniae
Lung mesothelium Asbestos Silicosis
Breast  HERV-K, inflammatory breast cancer
Stomach Helicobacter pylori Asbestos, EBV, chronic atrophic gastritis
Liver HBV, HCV, Clonorchis sinensis,  HDV, HIV type 1, Schistosoma japonicum, hemochromatosis
 Opisthorchis viverrini alpha-1-anti-trypsin deficiency, alcohol
Bile duct Clonorchis sinensis,  Bile acids-associated cholangitis 
 Opisthorchis viverrini
Gall bladder  Gall bladder stone-associated cholecystitis, Salmonella typhimurium
Pancreas  Chronic pancreatitis, alcoholism-associated pancreatitis, 
  hereditary pancreatitis, primary sclerosing cholangitis, alcohol
Colon & Rectum  Bile acids-associated coloproctitis, inflammatory bowel diseases, 
  cytomegalovirus, EBV, HPV, JCV, Bacteroides,  
  Clostridiumsepticum, Escherichia coli, Helicobacter pylori, 
  Streptococcus bovis, Streptococcus gallolyticus, 
  Schistosoma japonicum, asbestos
Bladder Schistosoma haematobium Cystitis, urinary catheter-associated cystitis
Anus HIV type 1, HPV type 16 HPV types 18, 33, anal fistula
Prostate  Prostatitis, proliferative inflammatory atrophy, gonorrhea, chlamydia, 
  mumps virus, Trichomonas vaginalis
Ovary Asbestos Pelvic inflammatory disease
Uterine cervix HPV types 16, 18, 31, 33, 35, 39,  HPV types 26, 53, 66, 67, 68, 70, 73, 82; 
 45, 51, 52, 56, 58, 59; HIV type 1 herpes simplex virus
Endometrium  Endometriosis
Penis HPV type 16 HIV type 1, HPV type 18
Vulva HPV type 16 HIV type 1, HPV types 18, 33; lichen sclerosis
Vagina HPV type 16 HIV type 1
Skin UV-associated skin inflammation Chronic osteomyelitis, HIV type 1, HPV types 5, 8; MCV
Melanoma  UV-associated skin inflammation
Non-melanomatous 
   skin cancer  Cutaneous HPV types
Central nerve  JCV
Endothelium 
   (Kaposi’s sarcoma) HIV type 1, KSHV HIV-2
Vasculature  Bortonella
Hodgkin’s lymphoma  EBV, HIV type 1 
Lymphoma EBV, HCV, HIV type 1,  HIV type 2, Hashimoto’s thyroiditis, Sjögren’s syndrome, 
 HTLV-1, KSHV childhood celiac disease, HBV, HTLV-1
Orbital lymphoma  Chlamydia psittaci 
Thyroid lymphoma  Hashimoto’s thyroiditis
Lymphoma in the 
   pleural cavity Pyothorax-associated lymphoma
MALT lymphoma Helicobacter pylori
Small-bowel lymphoma  Campylobacter jejuni
Continued on the following page
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cells converted from QR cells were also augmented in 
parallel with their malignant potential.18 Histologically, 
we observed emergence of abundant microvilli on the 
surface of the tumorigenic cells, a common phenomenon 
observed in other malignant tumor cell lines of rodent 
and human.19 
 We also determined several gene alterations through 
the inflammation-mediated conversion in this model 
(Fig. 3). The level of thymosin beta4 gene, which is 
known to be an actin-regulating protein and function for 
angiogenesis and wound healing, was elevated in all of 
the arising tumor cells. From the results of sense and an-
tisense cDNA transfection experiments, we revealed that 
thymosin beta4 gene was responsible for tumor form-
ing and/or metastasis through regulating cell motility.20 
The expression of E1AF, a member of the ets oncogenic 
transcription factor, was found high in the arising tumor 
lines.21 E1AF regulates tumor cell motility and invasive 
activities through induction of membrane-type 1-matrix 
metalloproteinase (MT-1-MMP) which converts the la-
tent form of matrix metalloproteinase-2 (MMP-2) into 
active form.21 Thus E1AF makes tumor cells invasive.21 
 We used foreign bodies to induce inflammation at 
the implanted site locally, which was to demonstrate 
direct association between inflammation and carcino-
genesis in vivo. Evidence for the effects of inflammatory 
cells on carcinogenesis was also demonstrated by the 
following three experiments: i) By histological examina-
tion, we found that neutrophils predominantly infiltrated 
into the inserted gelatin sponge in the very early phase.22 
One of the features of using gelatin sponge is that it is 
possible to collect the infiltrated inflammatory cells by 
treating the sponge with collagenase (Fig. 4). It was clear 
that inflammation definitely contributed to the conver-
sion of QR cells, since we found that the inflamed cells 
separated from the sponge could alter QR cells into le-
thally tumorigenic ones in the experiment of mixing the 
both two kinds of cells and injecting them in mice (Fig. 
2C.22 ii) To confirm the role of infiltrated neutrophils in 
inflammation, we eliminated neutrophils by administer-
ing anti-neutrophil antibody (RB6). As a result, nearly 
all the arising tumors in the mice, non-treated or treated 
with control IgG, acquired malignant phenotypes. On 
the other hand, in RB6 antibody-administered mice, 
arising tumors did not acquire malignant phenotypes 
Fig. 2. A mouse model of inflammation-related carcinogenesis. 
Regressive cells (QR) spontaneously regress in syngeneic normal 
mice after subcutaneous injection (A). Tumorigenic conversion 
was observed in QR cells injected into subcutaneously pre-
inserted gelatin sponge (B). Tumorigenic conversion was also 
observed in QR cells which were mixed with gelatin-sponge-
infiltrated inflammatory cells and injected in mice (C). The 
model was also utilized to screen candidate drugs to prevent 
inflammation-related carcinogenesis (D). 
Cutaneous lymphoma  Borrelia burgdorfer
DLBC lymphoma  Helicobacter pylori
Adult T-cell leukemia ATL (HTLV-1)
T-cell lymphoma  EBV
Burkitt’s lymphoma EBV
B-cell lymphoma   EBV
Primary effusion lymphoma KSHV
ATL, adult T-cell leukemia; COPD, chronic obstructive pulmonary disease; DLBC, diffuse large B-cell lymphoma; EBV, Epstein-Barr 
virus; HBV, hepatitis B virus; HCV, hepatitis C virus; HDV, hepatitis D virus; HERV-K, human endogenous retrovirus type K; HIV-1, 
human immunodeficiency virus; HPV, human papillomavirus; HTLV-1, human T-cell lymphotropic virus type 1; JCV, JC virus; KSHV, 
Kaposi sarcoma herpes virus; MALT, mucosa-associated lymphoid tissue; MCV, molluscum contagiosum virus.
*Outdoor air pollutions with PM10, PM2.5, NO2, SO2 and O3•PM2.5.
Table 1–Continued
Sites of inflammation- Causes of inflammation/pathological condition
related carcinogenesis Definitely carcinogenic Presumably carcinogenic
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(Fig. 2D).22 iii) We further confirmed the results in 
integrin-beta-2 knockout mice (C57BL/6JItgb2tm1Bay 
equivalent to CD18-deficient). Integrin-beta-2 is the key 
adhesion molecule for the migration of neutrophils into 
an inflammatory region. Neutrophil infiltration into 
gelatin sponge was abolished and acquisition of tumori-
genic phenotypes was suppressed in the integrin-beta-2 
knockout mice.22 
 These findings show that neutrophils are one of the 
main components of inflammation-associated tumor de-
velopment and progression. Interestingly, the capability 
of neutrophils to accelerate tumor cell malignancy varies 
depending on their activation phase, which we suggest 
from the finding that circulating or bone marrow neutro-
phils do not convert regressive cells into malignant ones 
but infiltrated (activated) neutrophils do.22
 
Fig. 3. Alteration of key molecules through foreign-body-induced carcinogenesis in mice. A diagram of stepwise molecular alterations in 
QR cells associated with acquisition of malignant phenotypes, accelerated by inflammation. 
Fig. 4. Advantages of using gelatin sponge for investigating inflammation-related carcinogenesi. There are advantages in using gelatin 
sponge for analyzing the inflammation-related carcinogenesis since sponge-infiltrated inflammatory cells can be collected by brief 
collagenase treatment. Then we can quantify inflammation by counting the number of infiltrated cells. Moreover, by using the infiltrated 
cells, we are able to analyze the inflammation by biological, molecular genetical, and cytological methods.
ROS produced by infiltrated inflammatory cells are 
the major cause for carcinogenesis 
We assumed that reactive oxygen species (ROS) would 
be key molecules that stimulate carcinogenic process 
since ROS act on both initiation and promotion of can-
cer. To determine the direct contribution of ROS to the 
carcinogenesis in our model, we used gp91phox gene-
knockout mice. Bactericidal function of neutrophils 
brings about generation of superoxide anions by forming 
NADPH oxidase complex (gp22phox, gp40phox, gp47phox, 
gp67phox, gp91phox and Rac1/Rac2) from interaction with 
cytochrome b558. The frequency of tumor development 
from the QR cells co-implanted with gelatin sponge was 
decreased in the gp91phox–/– mice.23 To determine wheth-
er phagocyte-derived ROS were actually involved in 
tumor development, we isolated phagocytes from wild-
type mice and transferred them into gp91phox–/– mice. 
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As a result, wild-type-derived phagocytes increased 
the frequencies of tumor development. In contrast, the 
phagocytes obtained from gp91phox gene-knockout mice 
did not have such activity.23 Moreover, administration 
of aminoguanidine, a broad inhibitor for inducible nitric 
oxide synthase, partially but significantly suppressed 
conversion in the model;24 thus we concluded that nitric 
oxide (NO) was also involved in the process. These re-
sults show that ROS and NO, derived from foreign-body-
induced inflammatory cells, are an intrinsic factor in the 
conversion of regressive cells to more malignant ones. 
 
Attempts to prevent inflammation-related carcino-
genesis 
When we determined the cause of inflammation-related 
carcinogenesis, it appeared that the carcinogenesis 
would be theoretically preventable: ROS are one of 
the most crucial genotoxic mediators to accelerate the 
carcinogenic process; then their antagonists, namely an-
tioxidative enzymes or antioxidants, will be effective to 
prevent the process (Fig. 2D).  
 Accordingly, we tried to induce an antioxidative 
enzyme, superoxide dismutase (SOD), at the inflamma-
tory site, hopefully by administration of orally active 
SOD, in our model. We used a newly developed SOD, 
named oxykine; as a result, the incidence of tumor for-
mation was significantly decreased due to induction of 
manganese-SOD (Mn-SOD) in the inflamed region, 
compared to the one under control vehicle treatment.25 It 
should be noted that Mn-SOD was induced secondarily 
to activation of host intestinal immunity instead of the 
drug’s direct action to the inflamed site. Thus Mn-SOD 
was induced at the inflamed site and the inflammation-
related carcinogenesis was suppressed. Based on these, 
rationales for effective prevention of inflammation-
related carcinogenesis will be either by suppressing ROS 
production of inflammatory cells or by blocking infiltra-
tion of inflammatory cells into the inflamed site.  
 
CONCLUSION & PERSPECTIVE
Inflammation, especially chronic one, is the definite 
cause for tumor development and progression, and it is 
well referred to as “inflammation-related carcinogen-
esis”. The pathogens that cause various types of inflam-
mation-related carcinogenesis are obviously unrelated, 
whereas the essential pathological feature in common 
is continuous inflammation: initially infiltration of ac-
tivated phagocytes/lymphocytes and then stimulated 
reaction of stroma composed mainly of fibroblasts and 
angiogenesis-related cells. It is assumed that continuous 
generation of ROS and NO by these infiltrated inflam-
matory cells is likely to injure normal cells. This could, 
in turn, cause compensatory cell proliferation, which 
will help accumulation of DNA damages/gene muta-
tions and effectively incorporate internal/external car-
cinogenic factors into the growth of stimulated normal 
cells. Apart from those, it has recently been revealed 
that inflammatory environments accelerate epigenetic 
alterations and the alterations could cause inflammation-
related carcinogenesis.26 All these events accompanying 
inflammation are essential to carcinogenesis. In this 
sense, we may understand that an inflammatory envi-
ronment is a niche for carcinogenesis.  
 Intriguingly, we noticed that all the chronic inflam-
mation and dysregulated immunity do not always lead to 
carcinogenesis; for instance, some of the chronic inflam-
matory diseases are not linked to cancer risk, and some 
are even leading to tumor regression. For instance, rheu-
matoid arthritis is not linked to cancer risk even though 
the inflammatory regions in rheumatoid arthritis patients 
show mutations of tumor suppressor genes at similar 
frequencies to those in the digestive tract tumors aris-
ing from chronic inflammatory reaction. Another thing 
to be noted here is that parasite (helminth, Trichuris 
suis) could diminish inflammatory response, and now 
its effects on inflammatory bowel diseases are under 
investigation. We may be able to determine the nature of 
inflammation which accelerates carcinogenesis by com-
paring the typical two types of inflammation, i.e., pro-
carcinogenic and anti-/unrelated-carcinogenic ones. 
 In our mouse model, inflammation induced by gela-
tin sponge insertion causes acute-phase inflammation, 
which will not become chronic since the sponge is ab-
sorbed spontaneously in the body. The actual inflamma-
tion leading to carcinogenesis is mostly chronic; possibly 
there is some link between acute-phase inflammation 
and chronic inflammatory diseases. A few techniques are 
available to pursue researches of this aspect: Apheresis 
technology has made it possible to eliminate granulo-
cytes and monocytes specifically from the patients with 
ulcerative colitis. By meta-analysis study, those patients 
with intensive granulocytes and monocytes adsorption 
make the higher rate of shift to clinical remission.27 It 
is important to find out whether there are some types of 
regulatory inflammatory cells in the early phase of in-
flammation that may maintain and prolong inflammation. 
We have not fully elucidated the mechanisms of inflam-
mation: how chronic inflammation is induced, activated, 
maintained and resolved; whether chronic inflammation 
is triggered by preexisting acute inflammation or it devel-
ops independently. We should now move on to identify 
key regulators for induction/maintenance of chronic in-
flammatory reaction that closely link to carcinogenesis, 
among which acute-phase inflammatory cells may be. 
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